Galecto, Inc. ( (GLTO) ) has released its Q2 earnings. Here is a breakdown of the information Galecto, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Galecto, Inc. is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics targeting fibrotic diseases and cancer, particularly in the oncology and liver disease sectors. In its latest earnings report, Galecto highlighted a strategic shift towards the development of GB3226 and GB1211, following the acquisition of global rights to Bridge Medicines’ BRM-1420 program. The company reported a net loss of $3.4 million for the second quarter of 2025, a reduction from the $5.3 million loss in the same period of 2024, attributed to decreased operating expenses. Despite a decrease in cash and cash equivalents to $10.2 million, Galecto remains focused on advancing its preclinical development programs. Looking forward, Galecto’s management is optimistic about the potential of GB3226 and GB1211, although it acknowledges the need for additional funding to support ongoing and future development activities.